ArticlePediatric nephrology (Berlin, Germany)2020
Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome.
Article in Pediatric nephrology (Berlin, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Acute kidney injury due to diarrhoeal diseases in children: a systematic review.BMJ paediatrics open · 2026Pooled it
- Eculizumab in severe pediatric STEC-HUS and its impact on neurological prognosis-a systematic review and meta-analysis.European journal of pediatrics · 2025Pooled it
- Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome.The Cochrane database of systematic reviews · 2025Pooled it
- Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome.The Cochrane database of systematic reviews · 2021Pooled it
- Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2025Trial
- Acute neurologic clinical manifestations and outcomes in children with thrombotic microangiopathies in paediatric intensive care units.European journal of pediatrics · 2026Observational
- Recombinant Human Fab Antibodies Differentially Neutralize Shiga Toxin in Renal Epithelial and Endothelial Cells.Toxins · 2026Article
- Shiga Toxin-Producing Escherichia coli Outbreak in Canadian Daycare Centers.JAMA network open · 2026Article
- Global population structure of Shiga toxin-producingMicrobial genomics · 2026Article
- Favorable Outcome With Eculizumab in Hemolytic Uremic Syndrome Presenting With Severe Neurological Complications: A Case Report.Case reports in nephrology · 2026Article
- Article
- Two cases of typical HUS in adults treated with an anti-C5 monoclonal antibody: a new perspective?Journal of nephrology · 2025Article
- Cryo-EM structures of engineered Shiga toxin-based immunogens capable of eliciting neutralizing antibodies with therapeutic potential against hemolytic uremic syndrome.Protein science : a publication of the Protein Society · 2025Article
- Case-Control Study of Factors Associated with Hemolytic Uremic Syndrome among Shiga Toxin-Producing Escherichia coli Patients, Ireland, 2017-2020.Emerging infectious diseases · 2025Article
- Rapid Enzymatic Detection of Shiga-Toxin-ProducingACS infectious diseases · 2024Article
- Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up.Pediatric nephrology (Berlin, Germany) · 2024Article
- Deletion of Sphingosine Kinase 2 Attenuates Acute Kidney Injury in Mice with Hemolytic-Uremic Syndrome.International journal of molecular sciences · 2024Article
- Constipation and hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2024Article
- Ultrasound analysis of different forms of hemolytic uremic syndrome in children.Frontiers in pediatrics · 2024Article
- Genetic Characterization of Intimin Gene (Toxins · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemolytic uremic syndrome (HUS) is a multisystemic disease. In a nationwide study, we characterized the incidence, clinical course, and prognosis of HUS caused by Shiga toxin (Stx)-producing Escherichia coli (STEC) strains with emphasis on risk factors, disease severity, and long-term outcome.
methodsThe data on pediatric HUS patients from 2000 to 2016 were collected from the medical records. STEC isolates from fecal cultures of HUS and non-HUS patients were collected from the same time period and characterized by whole genome sequencing analysis.
resultsFifty-eight out of 262 culture-positive cases developed verified (n = 58, 22%) STEC-HUS. Another 29 cases had probable STEC-HUS, the annual incidence of STEC-HUS being 0.5 per 100,000 children. Eleven different serogroups were detected, O157 being the most common (n = 37, 66%). Age under 3 years (OR 2.4), stx2 (OR 9.7), and stx2a (OR 16.6) were found to be risk factors for HUS. Fifty-five patients (63%) needed dialysis. Twenty-nine patients (33%) developed major neurological symptoms. Complete renal recovery was observed in 57 patients after a median 4.0 years of follow-up. Age under 3 years, leukocyte count over 20 × 10
conclusionsAge under 3 years, stx2, and stx2a were risk factors for HUS in STEC-positive children. However, serogroup or stx types did not predict the renal outcome or major CNS symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.